Following the publication of the above article, an interested reader drew to the authors' attention that, for the Transwell invasion assays shown in Fig. 5D on p. 1326, the images selected for the '0 μM benzidine / 0 μM curcumin' and '0 μM benzidine / 1 μM curcumin' experiments were overlapping, such that these data appeared to have been derived from the same original source. After having consulted their original data, the authors have realized that the '0 μM benzidine / 1 μM curcumin' data panel was selected incorrectly. The revised version of Fig. 5, showing the correct data for the '0 μM benzidine / 1 μM curcumin' data panel in Fig. 5D, is shown on the next page. The authors regret that this error went unnoticed prior to the publication of this article, and thank the Editor of International Journal of Oncology for allowing them the opportunity to publish this corrigendum. All the authors agree with the publication of this corrigendum; furthermore, they also apologize to the readership of the journal for any inconvenience caused.[International Journal of Oncology 50: 1321‑1329, 2017; DOI: 10.3892/ijo.2017.3887].
Keywords: EMT; ERK5/AP-1; benzidine; bladder cancer; curcumin.